<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth A Stewart, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shannon K Laughlin-Tommaso, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Kenneth Schoolmeester, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H20798632">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine fibroids (leiomyomas) are benign tumors that exhibit various forms of smooth muscle differentiation. The classic (conventional or typical) spindled form of leiomyoma is the most common pelvic tumor in females [
         <a href="#rid1">
          1-3
         </a>
         ]. Occasionally, patients with a uterine mass presumed to be a leiomyoma are subsequently diagnosed with a leiomyoma variant or leiomyosarcoma. There is a broad spectrum of leiomyoma variants: some have a single histologic finding that is associated with leiomyosarcoma, such as an increased mitotic index or severe cytologic atypia, while other growth pattern variants are defined by their capacity to spread to peritoneal surfaces or solid organs but are histologically benign. Finally, some smooth muscle tumors do not satisfy histologic criteria as being unequivocally benign or malignant and are, therefore, classified as having uncertain malignant potential.
        </p>
        <p>
         This topic will review variants of uterine leiomyomas; smooth muscle tumors of uncertain malignant potential (STUMP); leiomyomas with a disseminated, intravascular, or metastatic growth; and female genital tract leiomyomas associated with genetic disorders. The diagnosis and management of classic uterine leiomyomas, approaches to differentiating leiomyomas from various sarcomas, and tumors of uncertain malignant potential are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">
          "Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H44043070">
         <span class="h1">
          CRITERIA FOR CLASSIFICATION OF UTERINE SMOOTH MUSCLE TUMORS AS BENIGN OR MALIGNANT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Smooth muscle tumors are classified by their histologic features as benign, malignant, or, in some cases, of uncertain malignant potential. Gross characteristics may suggest that a tumor is benign or malignant, but microscopic examination is essential for proper classification since benign and malignant tumors can have overlapping macroscopic features. Disseminated peritoneal leiomyomatosis and metastasizing leiomyoma present with extrauterine spread, and such growth patterns should not be considered pathognomonic of malignancy. The 2020 World Health Organization classification system is shown in the table  (
         <a class="graphic graphic_table graphicRef95023" href="/z/d/graphic/95023.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histologic features
         </strong>
         – Three histologic features are considered when microscopically evaluating a uterine smooth muscle tumor:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mitotic index (counted per 10 high power fields)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Degree of cytologic atypia (graded as mild, moderate, severe)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of tumor cell necrosis, also known as coagulative necrosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, most
         <strong>
          spindled leiomyomas
         </strong>
         (also referred to as classic, typical, or conventional leiomyomas) have the following features:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mitotic index of fewer than five mitotic figures per 10 high power fields
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mild cytologic atypia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No tumor cell necrosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A diagnosis of
         <strong>
          leiomyosarcoma
         </strong>
         requires at least two of the following three features [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mitotic index of ≥10 mitotic figures per 10 high power fields
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate to severe cytologic atypia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of tumor cell necrosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of tumor cell necrosis
         </strong>
         – Tumor cell necrosis has a sharp transition between viable and nonviable tumor without intervening granulation tissue-like response resulting in the appearance of irregular "geographic shapes" [
         <a href="#rid5">
          5
         </a>
         ]. It must be distinguished from ischemic or hyaline-type necrosis, which is much more common and usually due to ischemia or hormonal changes. In some instances, necrosis can be ambiguous or have overlapping features of tumor cell necrosis and ischemic necrosis; in these cases, cytologic atypia and mitotic index may provide insight into the type of necrosis and possibly allow the pathologist to favor one type or the other.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of interpretation
         </strong>
         – It should be appreciated that while the above histologic features are considered objective values, there is an aspect of subjectivity in their interpretation based on the pathologist's experience and personal threshold for classification. For example, a study of interobserver variability in the interpretation of tumor cell necrosis among experienced gynecologic pathologists found only moderate agreement (kappa = 0.436) [
         <a href="#rid6">
          6
         </a>
         ]. Awareness of these issues is important for cases near the threshold for each parameter or tumors with unusual or difficult to classify features. Management of such cases may benefit from a dialogue between the clinician and pathologist and/or review by an expert gynecologic pathologist at a referral center.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1533068238">
         <span class="h1">
          PATHOLOGIC CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3697098964">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classic spindled uterine leiomyomas are very common, in contrast to leiomyoma variants, which have an estimated incidence of 1 to 2 percent in aggregate [
         <a href="#rid7">
          7
         </a>
         ]. Leiomyosarcoma is also rare compared with leiomyomas, although the exact incidence is controversial [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3211.html" rel="external">
          "Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1784688794">
         <span class="h2">
          Clinical implications
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is challenging to use clinical methods to differentiate tumors as benign or malignant and, therefore, be able to provide appropriate evaluation and treatment. The rarity of leiomyoma variants limits epidemiologic study and, by extension, data to guide diagnosis and treatment. Since most variants are defined by their histologic features, they are diagnosed only after surgical removal. Thus, the management of variants is primarily clinically relevant following myomectomy or hysterectomy that involved intraperitoneal morcellation of the uterine corpus, where persistence or recurrence is a possibility. Increasingly, abnormal magnetic resonance imaging may suggest atypical features in a presumed smooth muscle tumor and prompt surgical excision. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
         Expertise in these lesions varies among institutions, pathology laboratories, and gynecologists specializing in uterine smooth muscle tumors, and, if questions remain, pathology may benefit from review at a referral center. Gynecologic and medical oncologists may have additional expertise, particularly for tumors of uncertain malignant potential or disseminated or metastatic leiomyomas.
        </p>
        <p class="headingAnchor" id="H1167790">
         <span class="h1">
          VARIANTS OF LEIOMYOMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic variants of leiomyomas exhibit the same symptoms and signs as classic leiomyomas. There are no imaging modalities that distinguish histologic variants from classic spindled leiomyomas. Variants are diagnosed by pathologic examination following myomectomy or hysterectomy.
        </p>
        <p class="headingAnchor" id="H623742705">
         <span class="h2">
          Histologic variants
         </span>
        </p>
        <p class="headingAnchor" id="H1032305491">
         <span class="h3">
          Cellular leiomyoma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and classification
         </strong>
         – Cellular leiomyoma is defined as having increased cellularity relative to background myometrium  (
         <a class="graphic graphic_picture graphicRef121814" href="/z/d/graphic/121814.html" rel="external">
          picture 1
         </a>
         ). Careful evaluation is important to make this diagnosis correctly and differentiate this tumor from low-grade endometrial stromal sarcoma. Cellular leiomyomas are believed to make up no more than 5 percent of all leiomyomas [
         <a href="#rid10">
          10
         </a>
         ]. When diagnosed by hysterectomy, thoroughly sampled, and appropriately classified, cellular and hypercellular leiomyomas are benign with no risk of recurrence. However, since earlier studies have suggested that there may be rare cases of cellular leiomyomas with some molecular evidence of sarcoma-like signature, short-term surveillance is indicated in patients who underwent a uterine-sparing or intraperitoneal morcellating procedure due to risk of tissue remnant or misclassification [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is not a specific quantitative minimum degree of cellularity for a tumor to be considered cellular, and application of the term varies among pathologists. Marked cellularity resembling that of a typical endometrial stromal nodule or low-grade endometrial stromal sarcoma is sometimes referred to with the terms "cellular leiomyoma," "highly cellular leiomyoma," or, less commonly, "hypercellular leiomyoma." Care must be taken not to misclassify low-grade endometrial stromal sarcoma as cellular/hypercellular leiomyoma. (See
         <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">
          "Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'ESN and LG-ESS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cellular leiomyomas often have different gross appearance than conventional leiomyoma: their cut surface is generally more tan and less firm or rubbery. The spindle cells of cellular leiomyomas are arranged in bundles (fascicles) whereas the cells of low-grade endometrial stromal tumors are not bundled; instead, they are more haphazard in their architecture. Cellular leiomyomas, like classic leiomyomas, have thick-walled vessels. By contrast, classic low-grade endometrial stromal tumors have numerous spiral arterioles resembling those in proliferative phase endometrium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Immunohistochemistry and molecular cytogenetic testing can be helpful in difficult cases. Cellular leiomyomas express contractile proteins like smooth muscle actin, h-caldesmon, and desmin whereas classic low-grade endometrial stromal tumors express
         <em>
          IFITM1
         </em>
         and more robustly express
         <em>
          CD10
         </em>
         . Since several of these markers may be expressed by both categories of tumors, testing a panel of markers is most useful. Cytogenetic evaluation, often by way of fluorescence in situ hybridization, can facilitate classification. Classic low-grade endometrial stromal tumors can have recurrent chromosomal translocations, the most common being t(7;17)(p15;q21), which involves rearrangement of
         <em>
          JAZF1
         </em>
         and
         <em>
          SUZ12
         </em>
         (formerly
         <em>
          JJAZ1
         </em>
         ). Another more common rearrangement in low-grade endometrial stromal tumors is
         <em>
          PHF1
         </em>
         . In most tumors, identification of a
         <em>
          JAZF1
         </em>
         ,
         <em>
          SUZ12
         </em>
         , or
         <em>
          PHF1
         </em>
         rearrangement is diagnostic of a low-grade endometrial stromal tumor, but
         <em>
          PHF1
         </em>
         and
         <em>
          JAZF1
         </em>
         rearrangements have been reported in ossifying fibromyxoid tumor [
         <a href="#rid12">
          12,13
         </a>
         ], a rare soft-tissue tumor of intermediate malignancy that has yet to be reported as a primary uterine tumor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3494281521">
         <span class="h3">
          Leiomyoma with bizarre nuclei
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and classification
         </strong>
         – Leiomyoma with bizarre nuclei has focal, multifocal, or diffuse severe cytologic atypia in the form of nuclear enlargement, pleomorphism, hyperchromasia, multilobulated nuclei, and/or multinucleation  (
         <a class="graphic graphic_picture graphicRef121816" href="/z/d/graphic/121816.html" rel="external">
          picture 2
         </a>
         ). The recurrence risk of leiomyomas with bizarre nuclei after myomectomy is approximately 2 percent [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 2020 World Health Organization (WHO) recommends the term "leiomyoma with bizarre nuclei" rather than symplastic leiomyoma, atypical leiomyoma, or pleomorphic leiomyoma [
         <a href="#rid4">
          4
         </a>
         ]. The term "atypical leiomyoma" has been used inconsistently to describe different entities, including as a synonym for STUMP, which has a risk of recurrence, and as a synonym for leiomyoma with bizarre nuclei, which has no risk of recurrence when diagnosed by hysterectomy, appropriately sampled (such as one section/block per 1 cm of tumor), and correctly classified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Since leiomyoma with bizarre nuclei by definition has severe or significant cytologic atypia, STUMP and leiomyosarcoma should be excluded as part of the differential diagnosis. Smooth muscle tumors with significant cytologic atypia and a mitotic index of 10 or greater figures per 10 high power fields should be classified as leiomyosarcoma. Tumors with significant cytologic atypia that have fewer than 10 but a mitotic count near the threshold may be classified as STUMP; however, regardless of mitotic index, if tumor cell necrosis is present in a tumor that has severe cytologic atypia, it should be classified as leiomyosarcoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="local">
          'Smooth muscle tumors of uncertain malignant potential'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="local">
          'Criteria for classification of uterine smooth muscle tumors as benign or malignant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Leiomyomas with bizarre nuclei and fumarate hydratase (
         <em>
          FH
         </em>
         )-deficient leiomyomas have overlapping morphologic features.
         <em>
          FH
         </em>
         -deficient leiomyomas show a spectrum of prominent nucleoli, perinucleolar clearing, binucleation (in some instances, resembling Reed-Sternberg cells), eosinophilic intracytoplasmic inclusions, pseudoalveolar edema, and staghorn or hemangiopericytic vasculature. A comparative study of leiomyomas with bizarre nuclei and
         <em>
          FH
         </em>
         -deficient leiomyomas found staghorn vasculature as the only statistically significant feature by multivariate analysis of
         <em>
          FH
         </em>
         -deficient leiomyomas.
         <em>
          FH
         </em>
         immunohistochemistry can be helpful in distinguishing these two variants, but the immunostain is not 100 percent sensitive for all genetic alterations of
         <em>
          FH
         </em>
         . (See
         <a class="local">
          'Fumarate hydratase deficiency'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16698972">
         <span class="h3">
          Mitotically active leiomyoma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and classification
         </strong>
         – This variant is defined by the 2020 WHO Classification of Female Genital Tumors [
         <a href="#rid4">
          4
         </a>
         ] as an otherwise classic spindled leiomyoma (mild cytologic atypia, no tumor cell necrosis) but has an increased mitotic index &gt;10 mitotic figures per 10 high power fields  (
         <a class="graphic graphic_picture graphicRef121818" href="/z/d/graphic/121818.html" rel="external">
          picture 3
         </a>
         ). Some pathologists use a threshold of &gt;5 mitotic figures per 10 high power fields. Progesterone is thought to influence the mitotic index of smooth muscle tumors. Leiomyomas are more likely to have an increased mitotic count if they are excised during the secretory phase of the menstrual cycle, during pregnancy, or when patients are receiving exogenous progestins [
         <a href="#rid15">
          15-17
         </a>
         ]. Clinical manifestation and management of mitotically active leiomyomas are the same as for classic leiomyomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Mitotically active leiomyomas may have increased cellularity. Before making a diagnosis of cellular mitotically active leiomyoma, STUMP and low-grade endometrial stromal tumor should be excluded. Smooth muscle tumors with high mitotic counts (&gt;15 per 10 high power fields) are uncommon, and some have demonstrated aggressive behavior. Such tumors that have &gt;15 figures per 10 high power fields, are cytologically bland, and lack tumor cell necrosis should be classified as STUMP. (See
         <a class="local">
          'Smooth muscle tumors of uncertain malignant potential'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1167813">
         <span class="h3">
          Myxoid leiomyoma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and classification
         </strong>
         – Myxoid leiomyomas have an extracellular matrix composed of proteoglycans and glycosaminoglycans [
         <a href="#rid18">
          18
         </a>
         ]. This matrix is gray to blue by light microscopy, has a viscous quality, and separates spindled tumor cells into single cells and small clusters. Myxoid stroma can be present in various quantities and even found focally in otherwise classic leiomyomas. Generally, tumor volume is at least 50 percent myxoid to classify a tumor as myxoid leiomyoma [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Myxoid smooth muscle tumors are classified as leiomyoma when the tumor is well-circumscribed, has uniformly mild cytologic atypia, &lt;2 mitotic figures per 10 high power fields, and no tumor cell necrosis [
         <a href="#rid19">
          19
         </a>
         ]. In comparison, myxoid leiomyosarcoma has historically required two of three features to be present: significant cytologic atypia, ≥2 mitotic figures per 10 high power fields, and tumor cell necrosis. However, a study of uterine myxoid smooth muscle tumors emphasized the interface between tumor and surrounding myometrium as a critical prognostic feature: while most myxoid leiomyosarcomas infiltrate myometrium, in patients whose tumors satisfy criteria for myxoid leiomyosarcoma but were well-circumscribed, none experienced recurrence [
         <a href="#rid20">
          20
         </a>
         ]. Although data are limited, the authors suggested that a designation of STUMP may be more appropriate for what may typically be a well-circumscribed myxoid leiomyosarcoma. Optimal management of these lesions is unclear as the case reports are limited to small numbers of patients. (See
         <a class="local">
          'Smooth muscle tumors of uncertain malignant potential'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1167935">
         <span class="h3">
          Epithelioid leiomyoma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and classification
         </strong>
         – Epithelioid smooth muscle tumors are composed of rounded to polygonal cells that appear similar to epithelial cells and comprise at least 50 percent of the tumor [
         <a href="#rid21">
          21-23
         </a>
         ].
         <strong>
         </strong>
         There are limited data on morphologic features as predictive of malignant potential. An epithelioid smooth muscle tumor is classified as leiomyoma when it is well-circumscribed, lacks significant cytologic atypia, has a mitotic index of &lt;3 figures per 10 high power fields, and lacks tumor cell necrosis [
         <a href="#rid23">
          23
         </a>
         ]. Epithelioid smooth muscle tumors with significant nuclear atypia and either necrosis or &gt;5 mitotic figures per 10 high power fields are best considered leiomyosarcoma [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Aside from excluding carcinoma as part of the differential diagnosis when evaluating a potential epithelioid smooth muscle tumor, perivascular epithelioid cell (PEComa) tumor should also be considered. Like epithelioid smooth muscle tumors, PEComa forms nests and/or sheets of epithelial-like cells and spindle cells that have clear to granular eosinophilic cytoplasm [
         <a href="#rid24">
          24,25
         </a>
         ].
         <strong>
         </strong>
         PEComa is variably positive for smooth muscle immunohistochemical markers (desmin, h-caldesmon, smooth muscle actin) and melanocytic immunohistochemical markers (HMB45 and melan-A). Epithelioid smooth muscle tumors can be positive for HMB45 but are usually negative for melan-A [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Perivascular epithelioid cell (PEComa)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3387822489">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rarity of leiomyoma variants limits the amount of data available to guide management. In general, patients who underwent hysterectomy do not require additional follow-up, but those who underwent myomectomy, or procedures with risk of myometrial cell spread, warrant surveillance.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior hysterectomy
         </strong>
         – Hysterectomy by any route is considered curative for cellular leiomyoma, leiomyoma with bizarre nuclei, mitotically active leiomyoma, myxoid leiomyoma, and epithelioid leiomyoma as long as any uterus morcellation was performed outside of the peritoneum or within a containment system. No additional follow-up of these patients is needed. Patients who underwent supracervical hysterectomy should also be considered cured, unless the incision at the level of the cervix also incised the leiomyoma. Patients in whom the leiomyoma was incised when removing the uterine corpus have a risk of recurrence and are followed as if they had a myomectomy, which is discussed below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior myomectomy or intraperitoneal morcellation without containment
         </strong>
         – Patients who underwent myomectomy or intraperitoneal uterine morcellation without a containment system have a potential risk of persistence or recurrence of leiomyoma variant tumors. For patients with leiomyoma that are cellular, mitotically active, or have bizarre nuclei, surveillance imaging is performed to exclude residual tumor or recurrence, but the optimal frequency and duration of imaging are not known. The authors perform serial ultrasound examinations of the uterus for patients who underwent myomectomy and abdominal/pelvic magnetic resonance imaging for patients in whom there could have been intraabdominal dissemination at the time of the primary surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Epithelioid and myxoid smooth muscle tumors may be difficult to unequivocally classify as benign when myomectomy is performed due to potential intratumoral heterogeneity. The mitotic count threshold for diagnosing epithelioid and myxoid leiomyosarcomas is comparatively lower (5 and 2 mitotic figures/10 high power fields, respectively) than classic spindled leiomyosarcoma (10 mitotic figures/10 high power fields). In addition, data on myxoid smooth muscle tumors suggest myometrial infiltration is an important predictor of malignant potential [
         <a href="#rid20">
          20
         </a>
         ]. It is recommended that patients who underwent a uterine-sparing procedure or hysterectomy with uncontained intraperitoneal morcellation have annual surveillance, most commonly by pelvic ultrasound, and, if findings are concerning, pelvic magnetic resonance imaging.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H710161387">
         <span class="h1">
          SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANT POTENTIAL
         </span>
        </p>
        <p class="headingAnchor" id="H3806712">
         <span class="h2">
          Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine STUMP are a histologically and biologically heterogeneous collection of smooth muscle tumors that have features that do not satisfy defined criteria for leiomyoma, a leiomyoma variant, or leiomyosarcoma, although they do have features that raise concern for leiomyosarcoma. While these tumors have various combinations of cytologic atypia, mitotic index, and tumor cell necrosis, their overall findings are subdiagnostic of leiomyosarcoma but go beyond those of a typical leiomyoma or leiomyoma variant. (See
         <a class="local">
          'Criteria for classification of uterine smooth muscle tumors as benign or malignant'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3807065">
         <span class="h2">
          Clinical features and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentations of STUMP are the same as uterine leiomyomas and leiomyosarcomas (ie, uterine mass, abnormal uterine bleeding, and pelvic pain/pressure). Likewise, there is no imaging modality that can reliably distinguish these lesions. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         .)
        </p>
        <p>
         STUMP is diagnosed by pathologic evaluation of hysterectomy or myomectomy specimens. There are no guidelines regarding whether hysterectomy, if not previously performed, is required in patients diagnosed with STUMP by myomectomy. Similarly, the optimal management of the ovaries is not known. For such patients, a detailed discussion should be held with the patient to review tumor characteristics and the patient's plans for future pregnancy. Management options include hysterectomy or annual surveillance with pelvic imaging. More frequent surveillance, such as every four to six months, may be warranted, especially in the first several years after initial presentation and depending on the histologic features of the tumor and/or other factors (eg, the tumor was incompletely excised or was morcellated). If pelvic imaging is used, transvaginal ultrasound is recommended to detect the presence of new uterine masses and magnetic resonance imaging with gadolinium is recommended to evaluate the characteristics of any new uterine masses. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2872096067">
         <span class="h2">
          Risk of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Though the malignant potential of STUMP is difficult to predict by conventional morphologic analysis, all tumors appropriately classified as STUMP should be regarded as having some recurrent potential, even in patients who have undergone hysterectomy with an intact corpus.
        </p>
        <p>
         While data are limited, the recurrence risk of STUMP appears to vary with histologic features. In the 2020 World Health Organization (WHO) Classification of Female Genital Tumors, among the combinations of features found in STUMP, tumors that lack cytologic atypia and have a low mitotic index but have tumor cell necrosis carry the greatest risk of recurrence (up to 28 percent) [
         <a href="#rid4">
          4
         </a>
         ]. By contrast, tumors that lack cytologic atypia and tumor cell necrosis but have a high mitotic index (&gt;15 figures per 10 high-power fields) carry the lowest risk of recurrence (0 percent). These outcome data are aggregated from relatively small case series ranging from a total of 18 to 42 cases. Nevertheless, they underscore the diversity of tumors that can be classified as STUMP and that this category includes a range of smooth muscle tumors from exceptionally unusual leiomyomas, "low-grade" leiomyosarcomas, and developing "high-grade" leiomyosarcomas.
        </p>
        <p>
         In most instances, STUMPs that recur have declared their malignant potential and should be treated as sarcomas. Typical management includes surgical resection with or without removal of the ovaries depending on estrogen receptor (ER) status, age of the patient, and presences of metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/3211.html" rel="external">
          "Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis", section on 'Classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">
          "Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1167264">
         <span class="h1">
          LEIOMYOMAS WITH DISSEMINATED, INTRAVASCULAR, OR METASTATIC GROWTH PATTERNS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are distinctive growth patterns of smooth muscle tumors that have histologic features identical to classic uterine leiomyomas but with a capacity to disseminate through the peritoneal cavity, extend into the pelvic veins and vena cava, or metastasize to other distant sites, such as the lungs.
        </p>
        <p class="headingAnchor" id="H16699283">
         <span class="h2">
          Disseminated peritoneal leiomyomatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disseminated peritoneal leiomyomatosis (DPL; previously also called leiomyomatosis peritonealis disseminata) manifests as multiple nodules that occur across pelvic and peritoneal surfaces, often giving the impression of carcinomatosis [
         <a href="#rid27">
          27
         </a>
         ]. Although this disorder is benign, it appears that a small proportion (approximately &lt;5 percent) of DPL cases undergo malignant transformation.
        </p>
        <p>
         DPL primarily occurs in reproductive-age patients, although it has been described in postmenopausal patients and in a few male patients [
         <a href="#rid28">
          28
         </a>
         ]. Most patients are asymptomatic, and disease is usually discovered incidentally at the time of surgery. Symptoms, if present, may include abdominal mass or distension. DPL has also been reported in patients who do not have a history of uterine leiomyomas [
         <a href="#rid28">
          28
         </a>
         ]. A diagnosis of DPL is based upon histologic examination and correlation with operative/radiologic findings.
        </p>
        <p>
         Asymptomatic disease does not require treatment. Periodic regression and recurrence can occur, and medications that lower estrogen levels have been reported to resolve lesions for periods of time [
         <a href="#rid29">
          29
         </a>
         ]. Patients have been reported to develop recurrence, despite prior oophorectomy, after initiation of postmenopausal hormone therapy. Surgical resection is a reasonable approach in cases of large, symptomatic nodules. Hysterectomy is not indicated unless uterine symptoms are present.
        </p>
        <p>
         Clusters of disease within families have been described and suggest a hereditary element [
         <a href="#rid28">
          28,30
         </a>
         ]. Some data [
         <a href="#rid31">
          31-33
         </a>
         ] suggest DPL originates from hormonally driven transformation of subperitoneal mesenchyme while molecular studies propose that DPL is a clonal, metastatic process and has cytogenetic alterations similar to classic uterine leiomyomas [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         DPL is biologically different from iatrogenic seeding of the peritoneal cavity due to morcellation of leiomyoma(s) at the time of minimally invasive surgical procedures although the clinical presentation and management are similar [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108246.html" rel="external">
          "Uterine tissue extraction by morcellation: Techniques and clinical issues"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1167278">
         <span class="h2">
          Intravenous leiomyomatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous leiomyomatosis (IVL) is characterized by proliferations of histologically bland smooth muscle that extend in a plug-like fashion into uterine and pelvic veins, vena cava, and sometimes as far as the heart [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         IVL is found primarily in patients of reproductive age, although some cases have been described in postmenopausal patients [
         <a href="#rid21">
          21,29
         </a>
         ]. Patients with IVL may present with pelvic, abdominal, or cardiac symptoms, depending on the degree of extension of tumor plugs. Pelvic or abdominal symptoms include pain, abnormal uterine bleeding, and abdominal distension [
         <a href="#rid29">
          29
         </a>
         ]. A minority of patients present with significant dyspnea, an intracardiac mass, or evidence of right ventricular dysfunction (congestive heart failure, dyspnea, and syncope) [
         <a href="#rid21">
          21,37
         </a>
         ].
        </p>
        <p>
         IVL is diagnosed by pelvic imaging with computed tomography or magnetic resonance imaging showing a leiomyomatous or distorted uterus with projections into vasculature  (
         <a class="graphic graphic_diagnosticimage graphicRef66678" href="/z/d/graphic/66678.html" rel="external">
          image 1
         </a>
         ); intracardiac evaluation is performed by cardiac echocardiography [
         <a href="#rid38">
          38,39
         </a>
         ]. In some instances, the diagnosis is made following hysterectomy, when macroscopic and microscopic tumor plugs are present in vascular structures beyond the vicinity of an associated leiomyomatous mass. Treatment by surgical resection of the intravascular mass is required in most cases [
         <a href="#rid40">
          40-42
         </a>
         ].
        </p>
        <p>
         IVL can be associated with uterine leiomyomas, but some cases of IVL are not. IVL macroscopically and microscopically resembles typical leiomyomas [
         <a href="#rid21">
          21,43
         </a>
         ], although some histologic variants have been reported, such as tumors that are cellular, epithelioid, have a component of mature adipocytes, or a component of endometrial glands and stroma [
         <a href="#rid44">
          44,45
         </a>
         ]. Karyotypic findings in IVL are similar to the high-mobility group AT-hook (HMGA2) subgroup of classic leiomyomas [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
         The understanding of the pathogenesis of IVL suggests contiguous spread from the uterus to the vascular tree; hysterectomy is likely indicated at the time of surgical intervention. There are reports of improvement in symptoms with use of medications that decrease estrogen levels (eg, gonadotropin-releasing hormone agonists, aromatase inhibitors) [
         <a href="#rid48">
          48,49
         </a>
         ]. Since tumor recurrence has been reported from 7 months to 15 years after hysterectomy [
         <a href="#rid50">
          50,51
         </a>
         ], posttreatment surveillance by abdominal or thoracic imaging is suggested. There is some evidence that plugs of smooth muscle lesions may detach from IVL and travel hematogenously to the lung, resulting in a lesion suggestive of metastasizing leiomyoma, indicating necessity of serial chest imaging.
        </p>
        <p class="headingAnchor" id="H9293634">
         <span class="h2">
          Metastasizing leiomyoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastasizing leiomyoma is an uncommon condition in which solitary or multiple cytologic bland and mitotically inactive smooth muscle tumors are present at a distant location, most commonly the lungs (ie, pulmonary benign metastasizing leiomyoma [PBML]) [
         <a href="#rid52">
          52
         </a>
         ]. Such tumors are hormone dependent and express estrogen and progesterone receptors [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         Metastasizing leiomyoma occurs predominantly in patients of reproductive age or older. Most patients have a previous or current history of uterine leiomyomas. Patients can be asymptomatic (with incidental discovery by chest radiograph) or symptomatic (eg, chest pain, dyspnea, cough). In a review including 65 patients (median age at diagnosis 39 years) with PBML, respiratory symptoms and bilateral lesions occurred in over half of the patients (54 and 61 percent, respectively) [
         <a href="#rid52">
          52
         </a>
         ]. Median time to diagnosis of PBML from initial uterine leiomyoma surgery was six years (range &lt;1 to 14 years).
        </p>
        <p>
         Clonality studies suggest that metastasizing leiomyoma is derived from uterine leiomyomas [
         <a href="#rid54">
          54,55
         </a>
         ].
         <strong>
         </strong>
         Further cytogenetic data identified recurrent 19q and 22q deletions in both uterine and metastasized leiomyomas, indicating a subset may be predisposed to disseminate [
         <a href="#rid11">
          11,56
         </a>
         ]. Given data supporting a clonal process originating from uterine leiomyomas, it is likely that metastasizing leiomyoma spreads by vascular or lymphatic channels. Instances of metastasizing leiomyoma in patients with IVL have been reported.
        </p>
        <p>
         Metastasizing leiomyoma must be distinguished from pulmonary lymphangioleiomyomatosis (LAM), which presents with somewhat histologically similar lung lesions but with a more severe clinical phenotype. LAM, however, is a progressive proliferation of perivascular epithelioid cells (or LAM cells) along bronchial interstitium rather than usually inert nodular aggregates of conventional smooth muscle cells that involve alveolar parenchyma. (See
         <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
         Many patients with metastasizing leiomyoma experience an indolent course, but significant morbidity may occur [
         <a href="#rid29">
          29,57
         </a>
         ]. Expectant management is an option for asymptomatic disease. Surgical intervention (eg, oophorectomy, resection of metastatic lesion), use of agents that decrease estrogen (eg, gonadotropin-releasing hormone agonists, selective estrogen receptor modulators with antagonistic activity in the uterus, aromatase inhibitors) or progestins (eg, progesterone receptor antagonists), or anti-angiogenesis agents (anti-vascular endothelial growth factor [VEGF]) have resulted in tumor regression [
         <a href="#rid52">
          52,53,58
         </a>
         ]. While hysterectomy may not be required to treat extrauterine disease, if the patient has a uterine mass or masses, hysterectomy may be necessary to exclude a sarcoma.
        </p>
        <p class="headingAnchor" id="H23363872">
         <span class="h1">
          FEMALE GENITAL TRACT LEIOMYOMAS ASSOCIATED WITH GENETIC DISORDERS
         </span>
        </p>
        <p class="headingAnchor" id="H4017546808">
         <span class="h2">
          Fumarate hydratase deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fumarate hydratase (
         <em>
          FH
         </em>
         ) deficiency can occur as both a sporadic (ie, nonhereditary) event in leiomyomas or as a manifestation of hereditary leiomyomatosis and renal cell carcinoma (HLRCC), previously known as Reed syndrome [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         <em>
          FH
         </em>
         encodes fumarase, an enzyme that participates in the tricarboxylic acid cycle. The mechanism by which
         <em>
          FH
         </em>
         acts as a tumor suppressor is not fully understood, but other tricarboxylic acid cycle genes are known to act as tumor suppressors for other tumors, such as hereditary paragangliomas and succinate dehydrogenase. One mechanistic hypothesis posits that activation of hypoxia-induced metabolic pathways is involved in oncogenesis [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Morphologic features of leiomyomas affected by
         <em>
          FH
         </em>
         deficiency include prominent nucleoli, perinucleolar clearing, binucleation or multinucleation (in some instances, resembling Reed-Sternberg cells), eosinophilic intracytoplasmic inclusions, pseudoalveolar edema, and staghorn or hemangiopericytic vasculature  (
         <a class="graphic graphic_picture graphicRef121820" href="/z/d/graphic/121820.html" rel="external">
          picture 4
         </a>
         ). Whether a tumor is from a patient with a sporadic or hereditable deficiency cannot be distinguished by these morphologic features alone; dermatologic and medical genetic consultation are recommended for patients with uterine leiomyomas that have
         <em>
          FH
         </em>
         -deficient features [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fumarate hydratase-deficient leiomyomas
         </strong>
         –
         <em>
          FH
         </em>
         -deficient leiomyomas can occur in patients in whom no personal or family history of
         <em>
          FH
         </em>
         deficiency exists; a somatic mutation of one allele in a uterine myocyte results in the leiomyoma, leading all cells in the tumor to manifest
         <em>
          FH
         </em>
         deficiency. One explanation of
         <em>
          FH
         </em>
         -deficient leiomyomas is that marked metabolic stress drives their development [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When available,
         <em>
          FH
         </em>
         immunohistochemistry can be helpful to support a diagnosis of an
         <em>
          FH
         </em>
         -deficient leiomyoma (it shows loss of nuclear expression in
         <em>
          FH
         </em>
         -deficient tumors), but it is not 100 percent sensitive since some
         <em>
          FH
         </em>
         missense mutations still result in retained protein expression. The frequency remains to be determined of nonsyndromic
         <em>
          FH
         </em>
         loss due to chromosome 1 ring formation (deleting the copy of the
         <em>
          FH
         </em>
         gene on that chromosome) resulting in an
         <em>
          FH
         </em>
         -deficient histologic phenotype. [
         <a href="#rid59">
          59-62,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary leiomyomatosis and renal cell carcinoma
         </strong>
         – HLRCC is an autosomal dominant inherited disorder in which affected patients may develop cutaneous leiomyomas, uterine leiomyomas, and an aggressive form of papillary renal cell carcinoma. While it was originally thought that cutaneous leiomyomas were ubiquitous in this syndrome, subsequent reports suggest that cutaneous lesions are present in less than one-half of affected individuals [
         <a href="#rid65">
          65,66
         </a>
         ]. The lifetime risk of renal cell cancer in such patients is lower (ie, 15 to 20 percent), but screening and regular surveillance renal imaging is an important aspect of HLRCC management. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">
          "Hereditary leiomyomatosis and renal cell cancer (HLRCC)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HLRCC is caused by alterations in one copy of
         <em>
          FH
         </em>
         . Molecular studies have found different germline mutations associated with HLRCC, but they all result in absent or truncated proteins or changes in highly conserved amino acids. The second (normal) allele is usually deleted in tumor cells (ie, somatic loss of heterozygosity), confirming the role of
         <em>
          FH
         </em>
         as a tumor suppressor [
         <a href="#rid67">
          67-69
         </a>
         ]. Patients homozygous for
         <em>
          FH
         </em>
         mutations have a profound constitutional
         <em>
          FH
         </em>
         deficiency [
         <a href="#rid67">
          67,69
         </a>
         ]. The genotype-phenotype relationships for
         <em>
          FH
         </em>
         are an example of phenotypic heterogeneity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HLRCC has been associated with an increased risk of leiomyosarcoma in early literature. However, the distinctive morphology of
         <em>
          FH
         </em>
         -deficient leiomyomas may have led to their misclassification as leiomyosarcoma. Nevertheless, the risk of sarcoma associated with HLRCC is unclear, and, until there are more data, surveillance of patients who have undergone myomectomy for HLRCC appears to be indicated. HLRCC is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23364224">
         <span class="h2">
          Cowden syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome) is a multisystem disorder caused by germline mutation of the
         <em>
          PTEN
         </em>
         tumor suppressor gene that manifests with a range of hamartomatous lesions and benign tumors that involve mucocutaneous sites, the gastrointestinal tract, thyroid, and genitourinary tract. Those affected are also at an increased risk of developing endometrial, thyroid, and breast carcinoma [
         <a href="#rid70">
          70
         </a>
         ]. A systematic review of published cases of Cowden syndrome and other
         <em>
          PTEN
         </em>
         -related syndromes found uterine leiomyomas reported in 21 to 38 percent of patients [
         <a href="#rid71">
          71,72
         </a>
         ].
         <strong>
         </strong>
         Data are conflicted as to whether there is a significantly increased incidence of uterine leiomyomas in Cowden syndrome relative to the general population.
         <em>
          PTEN
         </em>
         mutation is not thought to play a pivotal role in sporadic uterine leiomyoma pathogenesis. (See
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Cowden syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12062357">
         <span class="h2">
          Diffuse leiomyomatosis (Alport syndrome)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The X-linked form of Alport syndrome, defined by nephropathy, deafness, and sometimes ocular anomalies, is caused by germline mutation of
         <em>
          COL4A5
         </em>
         . Patients with Alport syndrome who also develop diffuse leiomyomatosis (which can involve the esophagus, tracheobronchial tree, vulva, and/or uterus) have an underlying germline deletion of both
         <em>
          COL4A5
         </em>
         and
         <em>
          COL4A6
         </em>
         , typifying the definition of a contiguous gene syndrome [
         <a href="#rid73">
          73
         </a>
         ]. On chromosome Xq22.3, genes for the alpha-5 and alpha-6 monomers of nonfibrillar basement membrane (type IV) collagen (
         <em>
          COL4A5
         </em>
         and
         <em>
          COL4A6
         </em>
         ) are arranged in a head-to-head fashion and share a common promoter region. Pathogenetic, submicroscopic deletions of the overlapping promoters and adjacent 5' regions may be as small as 13.4 kb [
         <a href="#rid74">
          74
         </a>
         ]. Interestingly, the mRNA of
         <em>
          COL4A6
         </em>
         is increased approximately twofold in nonsyndromic typical uterine leiomyomas but decreased nearly 14-fold in uterine leiomyosarcomas relative to myometrium [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3340572426">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111091.html" rel="external">
          "Society guideline links: Uterine fibroids (leiomyomas)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20798640">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant potential of uterine smooth muscle tumors is currently assessed by degree of cytologic atypia, mitotic index, and presence of tumor cell necrosis. Uterine leiomyoma variants can have the same clinical presentations as classic uterine leiomyomas and sarcomas, such as a solitary mass or numerous masses, abnormal uterine bleeding, and pelvic pain/pressure. No imaging modality reliably distinguishes these leiomyoma variants from classic leiomyoma or sarcomas. (See
         <a class="local">
          'Criteria for classification of uterine smooth muscle tumors as benign or malignant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic variants of leiomyomas include cellular, bizarre nuclei, mitotically active, epithelioid, and myxoid, among others. They are diagnosed following myomectomy or hysterectomy. Although their management is generally the same as classic leiomyomas, surveillance with pelvic imaging may be required if incompletely removed. (See
         <a class="local">
          'Variants of leiomyomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smooth muscle tumors of uncertain malignant potential (STUMP) have some features of leiomyosarcoma, but they do not satisfy diagnostic criteria. Furthermore, the features of STUMP go beyond what is expected in established leiomyoma variants. STUMP is diagnosed following myomectomy or hysterectomy. There are no definitive guidelines regarding whether hysterectomy, if not already performed, is required in patients with this diagnosis, but long-term follow-up is required at minimum. Optimal management of the ovaries is also not known. (See
         <a class="local">
          'Smooth muscle tumors of uncertain malignant potential'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conditions such as metastasizing leiomyoma and intravenous leiomyomatosis present with symptoms related to involved disease sites, such as lung and vena caval lesions causing dyspnea. Many of these conditions are responsive to antiestrogenic therapy. (See
         <a class="local">
          'Leiomyomas with disseminated, intravascular, or metastatic growth patterns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some cases of leiomyomas are associated with genetic disorders. Pathologic reporting of a fumarate hydratase-deficient leiomyoma should prompt discussion of referral to a genetic counselor for risk evaluation of hereditary leiomyomatosis renal cell carcinoma in the patient and family members and initiation of surveillance for renal cell cancer. (See
         <a class="local">
          'Fumarate hydratase deficiency'
         </a>
         above and
         <a class="local">
          'Cowden syndrome'
         </a>
         above and
         <a class="local">
          'Diffuse leiomyomatosis (Alport syndrome)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2564590421">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Bradley Quade, MD, PhD, and Rochelle Garcia, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.
          </a>
         </li>
         <li class="breakAll">
          https://tumourclassification.iarc.who.int/chapters/34 (Accessed on July 15, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol 2013; 37:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arleo EK, Schwartz PE, Hui P, McCarthy S. Review of Leiomyoma Variants. AJR Am J Roentgenol 2015; 205:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG 2017; 124:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids. Nat Rev Dis Primers 2016; 2:16043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson N, Rollason TP. Recent advances in the pathology of smooth muscle tumours of the uterus. Histopathology 2001; 39:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebre-Medhin S, Nord KH, Möller E, et al. Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors. Am J Pathol 2012; 181:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoolmeester JK, Sukov WR, Maleszewski JJ, et al. JAZF1 rearrangement in a mesenchymal tumor of nonendometrial stromal origin: report of an unusual ossifying sarcoma of the heart demonstrating JAZF1/PHF1 fusion. Am J Surg Pathol 2013; 37:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly A, Mills AM, McKenney JK, et al. Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases. Am J Surg Pathol 2013; 37:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrone T, Dehner LP. Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am J Surg Pathol 1988; 12:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol 1990; 21:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi K, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willems SM, Wiweger M, van Roggen JF, Hogendoorn PC. Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist? Virchows Arch 2010; 456:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins KA, Bell S, Kempson RL. Myxoid smooth muscle tumors of the uterus. Mod Pathol 2001; 14:132A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parra-Herran C, Schoolmeester JK, Yuan L, et al. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms. Am J Surg Pathol 2016; 40:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010; 17:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurman RJ, Norris HJ. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases. Cancer 1976; 37:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prayson RA, Goldblum JR, Hart WR. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. Am J Surg Pathol 1997; 21:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vang R, Kempson RL. Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoolmeester JK, Howitt BE, Hirsch MS, et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol 2014; 38:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howitt BE, Schoolmeester JK, Quade BJ. Immunohistochemical analysis of HMB-45, MelanA, CathepsinK in a series of 35 uterine leiomyosarcomas. Mod Pathol 2013; 26:279A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardman WJ 3rd, Majmudar B. Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. South Med J 1996; 89:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halama N, Grauling-Halama SA, Daboul I. Familial clustering of Leiomyomatosis peritonealis disseminata: an unknown genetic syndrome? BMC Gastroenterol 2005; 5:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaquero ME, Magrina JF, Leslie KO. Uterine smooth-muscle tumors with unusual growth patterns. J Minim Invasive Gynecol 2009; 16:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quade BJ, McLachlin CM, Soto-Wright V, et al. Disseminated peritoneal leiomyomatosis. Clonality analysis by X chromosome inactivation and cytogenetics of a clinically benign smooth muscle proliferation. Am J Pathol 1997; 150:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pieslor PC, Orenstein JM, Hogan DL, Breslow A. Ultrastructure of myofibroblasts and decidualized cells in leiomyomatosis peritonealis disseminata. Am J Clin Pathol 1979; 72:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavassoli FA, Norris HJ. Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations. Int J Gynecol Pathol 1982; 1:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aterman K, Fraser GM, Lea RH. Disseminated peritoneal leiomyomatosis. Virchows Arch A Pathol Anat Histol 1977; 374:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidman MA, Oduyebo T, Muto MG, et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012; 7:e50058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordulu Z, Dal Cin P, Chong WW, et al. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer 2010; 49:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worley MJ Jr, Aelion A, Caputo TA, et al. Intravenous leiomyomatosis with intracardiac extension: a single-institution experience. Am J Obstet Gynecol 2009; 201:574.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade LA, Torresan RZ, Sales JF Jr, et al. Intravenous leiomyomatosis of the uterus. A report of three cases. Pathol Oncol Res 1998; 4:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fasih N, Prasad Shanbhogue AK, Macdonald DB, et al. Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics 2008; 28:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun C, Wang XM, Liu C, et al. Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography. Am J Surg 2010; 200:e41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelli P, Caronno R, Piffaretti G, Tozzi M. Intravenous uterine leiomyomatosis with right heart extension: successful two-stage surgical removal. Ann Vasc Surg 2006; 20:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García Rinaldi R, Pérez Hernández J, Corbalá AR, et al. Surgical treatment of multiple intracardiac and pulmonary artery tumor implants embolic from uterine intravascular leiomyomatosis. Bol Asoc Med P R 2007; 99:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Yang J, Huang H, et al. Management of intravenous leiomyomatosis with intracaval and intracardiac extension. Obstet Gynecol 2012; 120:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buza N, Xu F, Wu W, et al. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Hum Pathol 2014; 45:1885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clement PB, Young RH, Scully RE. Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features. Am J Surg Pathol 1988; 12:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr RJ, Hui P, Buza N. Intravenous leiomyomatosis revisited: an experience of 14 cases at a single medical center. Int J Gynecol Pathol 2015; 34:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quade BJ, Dal Cin P, Neskey DM, et al. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case. Mod Pathol 2002; 15:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Cin P, Quade BJ, Neskey DM, et al. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer 2003; 36:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodner-Adler B, Bartl M, Wagner G. Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma? Anticancer Res 2009; 29:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biri A, Korucuoglu U, Zumrutbas N, et al. Intravenous leiomyomatosis treated with aromatase inhibitor therapy. Int J Gynaecol Obstet 2008; 101:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grella L, Arnold TE, Kvilekval KH, Giron F. Intravenous leiomyomatosis. J Vasc Surg 1994; 20:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AT 3rd, Symmonds RE, Gaffey TA. Recurrent pelvic intravenous leiomyomatosis. Obstet Gynecol 1981; 57:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su H, Fan R, Yang H, et al. Pulmonary benign metastasizing leiomyoma in patients aged 45 years and younger: clinical features and novelty in treatment. BMC Pulm Med 2023; 23:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivera JA, Christopoulos S, Small D, Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab 2004; 89:3183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patton KT, Cheng L, Papavero V, et al. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol 2006; 19:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tietze L, Günther K, Hörbe A, et al. Benign metastasizing leiomyoma: a cytogenetically balanced but clonal disease. Hum Pathol 2000; 31:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucci MR, Drapkin R, Dal Cin P, et al. Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol 2007; 31:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awonuga AO, Shavell VI, Imudia AN, et al. Pathogenesis of benign metastasizing leiomyoma: a review. Obstet Gynecol Surv 2010; 65:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motegi M, Takayanagi N, Sando Y, et al. [A case of so-called benign metastasizing leiomyoma responsive to progesterone]. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison WJ, Andrici J, Maclean F, et al. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. Am J Surg Pathol 2016; 40:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005; 205:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollard PJ, Brière JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14:2231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph NM, Solomon DA, Frizzell N, et al. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients. Am J Surg Pathol 2015; 39:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bortoletto P, Lindsey JL, Yuan L, et al. Hereditary leiomyomatosis and renal cell cancer: Cutaneous lesions &amp; atypical fibroids. Case Rep Womens Health 2017; 15:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 2013; 369:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan E, Rabban JT, Mak J, et al. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC). Am J Surg Pathol 2019; 43:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhola PT, Gilpin C, Smith A, Graham GE. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC). Fam Cancer 2018; 17:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003; 12:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008; 9:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 1993; 261:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal Y, Peissel B, Renieri A, et al. LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis. Am J Hum Genet 1999; 64:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15676 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548202" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7026295" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Uterine leiomyomata: etiology, symptomatology, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1835500" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Treatment of abnormal uterine bleeding with the gynecologic resectoscope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1835500" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Treatment of abnormal uterine bleeding with the gynecologic resectoscope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8179071" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23552382" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26397344" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Review of Leiomyoma Variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28296146" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epidemiology of uterine fibroids: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27335259" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11683931" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Recent advances in the pathology of smooth muscle tumours of the uterus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16320247" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22796436" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23629446" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : JAZF1 rearrangement in a mesenchymal tumor of nonendometrial stromal origin: report of an unusual ossifying sarcoma of the heart demonstrating JAZF1/PHF1 fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23552381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337336" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2307449" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mitotically active leiomyomas of the uterus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2929683" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mitotic activity in uterine leiomyomas during the menstrual cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19705152" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Myxoid smooth muscle tumors of the uterus
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26866354" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20179432" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/56982" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9130984" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756764" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24418852" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunohistochemical analysis of HMB-45, MelanA, CathepsinK in a series of 35 uterine leiomyosarcomas
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8604458" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16223449" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Familial clustering of Leiomyomatosis peritonealis disseminata: an unknown genetic syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423058" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Uterine smooth-muscle tumors with unusual growth patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9176406" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Disseminated peritoneal leiomyomatosis. Clonality analysis by X chromosome inactivation and cytogenetics of a clinically benign smooth muscle proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/506999" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ultrastructure of myofibroblasts and decidualized cells in leiomyomatosis peritonealis disseminata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7184891" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/141779" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Disseminated peritoneal leiomyomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23189178" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20842731" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729144" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intravenous leiomyomatosis with intracardiac extension: a single-institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9555121" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intravenous leiomyomatosis of the uterus. A report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001649" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Leiomyomas beyond the uterus: unusual locations, rare manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20409533" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16583249" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intravenous uterine leiomyomatosis with right heart extension: successful two-stage surgical removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17616048" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Surgical treatment of multiple intracardiac and pulmonary artery tumor implants embolic from uterine intravascular leiomyomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23168766" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Management of intravenous leiomyomatosis with intracaval and intracardiac extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25033729" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3202247" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25675187" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Intravenous leiomyomatosis revisited: an experience of 14 cases at a single medical center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904348" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12508249" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19331193" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280477" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intravenous leiomyomatosis treated with aromatase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7990195" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intravenous leiomyomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7465135" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Recurrent pelvic intravenous leiomyomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37189093" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pulmonary benign metastasizing leiomyoma in patients aged 45 years and younger: clinical features and novelty in treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15240591" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16357844" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665925" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Benign metastasizing leiomyoma: a cytogenetically balanced but clonal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460458" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20214834" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pathogenesis of benign metastasizing leiomyoma: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8366630" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : [A case of so-called benign metastasizing leiomyoma responsive to progesterone].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26574848" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15586379" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15987702" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26457356" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29593997" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Hereditary leiomyomatosis and renal cell cancer: Cutaneous lesions&amp;atypical fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23738515" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Characterization of uterine leiomyomas by whole-genome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31162287" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29423582" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12761039" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18366737" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865300" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21659347" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18972196" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cowden syndrome: a critical review of the clinical literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24136893" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8356449" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915944" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15101043" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
